Panbela Therapeutics is engaged in advancing the commercial development of a proprietary polyamine analogue for pancreatic cancer. Co. has exclusively licensed the worldwide rights to this compound, which has been designated as SBP-101, from the University of Florida Research Foundation, Inc. Co.'s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition, a metabolic pathway of critical importance in multiple tumor types. The PBLA stock yearly return is shown above.
The yearly return on the PBLA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PBLA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|